Outcomes of chronic limb-threatening ischemia revascularization in patients with chronic kidney disease in the BEST-CLI trial

IF 3.6 2区 医学 Q1 PERIPHERAL VASCULAR DISEASE Journal of Vascular Surgery Pub Date : 2025-04-01 Epub Date: 2025-01-23 DOI:10.1016/j.jvs.2024.12.128
Mahmoud B. Malas MD, MHS, RPVI, FACS , Mohammed Hamouda MD , Alik Farber MD, MBA, FACS, DFSVS , Matthew T. Menard MD , Michael S. Conte MD , Kenneth Rosenfield MD, MSC , Michael B. Strong MA , Gheorghe Doros PhD, MBA , Richard J. Powell MD , Carlos Mena-Hurtado MD , Warren Gasper MD , Marc L. Schermerhorn MD , Sara Allievi MD , Kim G. Smolderen PhD , Michael D. Dake MD , Jennifer A. Rymer MD, MBA , Katherine R. Tuttle MD, FASN, FACP, FNKF
{"title":"Outcomes of chronic limb-threatening ischemia revascularization in patients with chronic kidney disease in the BEST-CLI trial","authors":"Mahmoud B. Malas MD, MHS, RPVI, FACS ,&nbsp;Mohammed Hamouda MD ,&nbsp;Alik Farber MD, MBA, FACS, DFSVS ,&nbsp;Matthew T. Menard MD ,&nbsp;Michael S. Conte MD ,&nbsp;Kenneth Rosenfield MD, MSC ,&nbsp;Michael B. Strong MA ,&nbsp;Gheorghe Doros PhD, MBA ,&nbsp;Richard J. Powell MD ,&nbsp;Carlos Mena-Hurtado MD ,&nbsp;Warren Gasper MD ,&nbsp;Marc L. Schermerhorn MD ,&nbsp;Sara Allievi MD ,&nbsp;Kim G. Smolderen PhD ,&nbsp;Michael D. Dake MD ,&nbsp;Jennifer A. Rymer MD, MBA ,&nbsp;Katherine R. Tuttle MD, FASN, FACP, FNKF","doi":"10.1016/j.jvs.2024.12.128","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Chronic limb-threatening ischemia (CLTI) in patients with chronic kidney disease (CKD) has a high risk of poor outcomes. We aimed to compare the outcomes of lower extremity revascularization in patients with CLTI stratified by CKD severity in patients enrolled in the prospective, randomized Best Endovascular vs Best Surgical Therapy in Patients with CLTI (BEST-CLI) trial.</div></div><div><h3>Methods</h3><div>The BEST-CLI trial dataset was queried to categorize patients into three groups according to CKD stage. Group A includes non-CKD and CKD stages &lt;3; group B includes stage 3 and stage 4 CKD patients; and group C includes stage 5 CKD and dialysis-dependent patients. Furthermore, spline modeling was performed across the range of estimated glomerular filtration rate (eGFR, mL/min/1.73 m<sup>2</sup>) observed in study participants to identify a threshold eGFR that impacted the primary trial outcomes: major adverse limb events (MALEs; defined as above-ankle amputation or major reintervention) or all-cause mortality, by surgical or endovascular revascularization (as-treated analysis). Kaplan-Meier and multivariate Cox regression analyses were used to assess association of CKD risk groups with the outcomes.</div></div><div><h3>Results</h3><div>A total of 1797 patients were included. Group C patients had double the risk of amputation (hazard ratio [HR], 2.13; <em>P</em> &lt; .001), MALE, or all-cause mortality (HR, 2.05; <em>P</em> &lt; .001) and more than triple the risk of all-cause mortality (HR, 3.40; <em>P</em> &lt; .001) compared with group A. In dialysis-dependent patients, endovascular therapy was associated with better survival, but twice the risk of reintervention compared with surgical revascularization. According to spline model analysis, hazard of MALE or all-cause mortality increased sharply at eGFR &lt;30. The hazard ratios for eGFR &lt;30 vs ≥60 were 2.03 (95% confidence interval [CI], 1.68-2.43; <em>P</em> &lt; .001) and 3.46 (95% CI, 2.80-4.27; <em>P</em> &lt; .001) for MALE and mortality, respectively. At eGFR &lt;30, there was no difference in the primary outcome by treatment received (surgical or endovascular revascularization).</div></div><div><h3>Conclusions</h3><div>The progressive nature of renal impairment in patients with CLTI threatens their survival and limb salvage and may reduce the relative benefit of open vs endovascular revascularization seen in the overall BEST-CLI trial population. In dialysis-dependent patients, endovascular therapy was associated with lower mortality but increased reintervention rate.</div></div>","PeriodicalId":17475,"journal":{"name":"Journal of Vascular Surgery","volume":"81 4","pages":"Pages 945-956.e3"},"PeriodicalIF":3.6000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Vascular Surgery","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0741521425000035","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/23 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Chronic limb-threatening ischemia (CLTI) in patients with chronic kidney disease (CKD) has a high risk of poor outcomes. We aimed to compare the outcomes of lower extremity revascularization in patients with CLTI stratified by CKD severity in patients enrolled in the prospective, randomized Best Endovascular vs Best Surgical Therapy in Patients with CLTI (BEST-CLI) trial.

Methods

The BEST-CLI trial dataset was queried to categorize patients into three groups according to CKD stage. Group A includes non-CKD and CKD stages <3; group B includes stage 3 and stage 4 CKD patients; and group C includes stage 5 CKD and dialysis-dependent patients. Furthermore, spline modeling was performed across the range of estimated glomerular filtration rate (eGFR, mL/min/1.73 m2) observed in study participants to identify a threshold eGFR that impacted the primary trial outcomes: major adverse limb events (MALEs; defined as above-ankle amputation or major reintervention) or all-cause mortality, by surgical or endovascular revascularization (as-treated analysis). Kaplan-Meier and multivariate Cox regression analyses were used to assess association of CKD risk groups with the outcomes.

Results

A total of 1797 patients were included. Group C patients had double the risk of amputation (hazard ratio [HR], 2.13; P < .001), MALE, or all-cause mortality (HR, 2.05; P < .001) and more than triple the risk of all-cause mortality (HR, 3.40; P < .001) compared with group A. In dialysis-dependent patients, endovascular therapy was associated with better survival, but twice the risk of reintervention compared with surgical revascularization. According to spline model analysis, hazard of MALE or all-cause mortality increased sharply at eGFR <30. The hazard ratios for eGFR <30 vs ≥60 were 2.03 (95% confidence interval [CI], 1.68-2.43; P < .001) and 3.46 (95% CI, 2.80-4.27; P < .001) for MALE and mortality, respectively. At eGFR <30, there was no difference in the primary outcome by treatment received (surgical or endovascular revascularization).

Conclusions

The progressive nature of renal impairment in patients with CLTI threatens their survival and limb salvage and may reduce the relative benefit of open vs endovascular revascularization seen in the overall BEST-CLI trial population. In dialysis-dependent patients, endovascular therapy was associated with lower mortality but increased reintervention rate.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
BEST-CLI试验中慢性肾脏疾病患者慢性肢体威胁缺血血运重建术的结果
背景:慢性肾脏疾病(CKD)患者的慢性肢体威胁缺血(CLTI)具有较高的不良预后风险。我们的目的是比较前瞻性随机CLTI患者最佳血管内治疗与最佳手术治疗(Best - cli)试验中按CKD严重程度分层的CLTI患者下肢血运重建术的结果。方法:查询BEST-CLI试验数据集,根据CKD分期将患者分为三组。A组包括在研究参与者中观察到的非CKD和CKD 2期,以确定影响主要试验结果的eGFR阈值:主要肢体不良事件(男性;定义为踝关节以上截肢或主要再干预)或全因死亡率,通过手术或血管内血管重建术(作为治疗分析)。Kaplan-Meier和多变量Cox回归分析用于评估CKD危险组与结果的关联。结果:共纳入1797例患者。C组患者截肢风险为2倍(危险比[HR], 2.13;P < 0.001)、男性或全因死亡率(HR, 2.05;P < 0.001),全因死亡风险超过三倍(HR, 3.40;结论:CLTI患者肾脏损害的进行性威胁到他们的生存和肢体保留,并可能降低BEST-CLI总体试验人群中开放与血管内血运重建术的相对获益。在依赖透析的患者中,血管内治疗与较低的死亡率相关,但增加了再干预率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
7.70
自引率
18.60%
发文量
1469
审稿时长
54 days
期刊介绍: Journal of Vascular Surgery ® aims to be the premier international journal of medical, endovascular and surgical care of vascular diseases. It is dedicated to the science and art of vascular surgery and aims to improve the management of patients with vascular diseases by publishing relevant papers that report important medical advances, test new hypotheses, and address current controversies. To acheive this goal, the Journal will publish original clinical and laboratory studies, and reports and papers that comment on the social, economic, ethical, legal, and political factors, which relate to these aims. As the official publication of The Society for Vascular Surgery, the Journal will publish, after peer review, selected papers presented at the annual meeting of this organization and affiliated vascular societies, as well as original articles from members and non-members.
期刊最新文献
Multi-segmental aneurysmal disease in an adult with type A interrupted aortic arch. Factors Associated with Myocardial Infarction Among Patients Without Prior History of Coronary Artery Diseases Following Carotid Artery Revascularization. Tibial Access is Associated with Tibial Intervention in Claudicants. To Regress or Not to Regress? Outcomes of Aneurysm Sac Behavior After EVAR: A Systematic Review and Meta-Analysis. Retrospective multicenter Evaluation of cold-stored saphenous Vein Allografts in peripheral arterial diSease (REVAS Study).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1